Product Image

Contributor Information

  • Institute University College London (UCL)

Tool Details

  • Tool name: Anti-CD22 [RFB-4]
  • Clone: RFB-4
  • Tool type: Antibodies
  • Tool sub-type: Primary antibody
  • Class: Monoclonal
  • Conjugate: Unconjugated
  • Reactivity: Human
  • Host: Mouse
  • Molecular weight of the target: 153 kDa
  • Application: FACS ; IHC ; IF
  • Strain: Balb/c
  • Description: Establishing origin of B cell malignancies, especially discriminating between immature (bone marrow type) and peripheral B cell leukaemias and lymphomas. Suitable for use as an immunotoxin against human B cell leukaemias and lymphomas.
  • Immunogen: Tonsil lymphocytes
  • Isotype: IgG1
  • Research area: Cell biology; Cancer; Cell signaling and signal transduction; Immunology; Stem cell biology
  • Myeloma used: P3X63Ag8

  • For Research Use Only

Target Details

  • Target: CD22
  • Target molecular weight: 153 kDa
  • Target background: Establishing origin of B cell malignancies, especially discriminating between immature (bone marrow type) and peripheral B cell leukaemias and lymphomas. Suitable for use as an immunotoxin against human B cell leukaemias and lymphomas.

Application Details

  • Application: FACS ; IHC ; IF

Handling

  • Format: Liquid
  • Concentration: 1 mg/ml
  • Storage buffer: PBS with 0.02% azide
  • Storage conditions: -80°C
  • Shipping conditions: Shipping at 4°C

Documentation

Related Tools

Product Image

Anti-Integrin Beta 3 (GPIIIa, CD61) [AP-2]

#153745
Product Image

Anti-Rab11a [STo 2F3]

#151193
Product Image

Anti-MCM5 [A2.1G2.A7.C12]

#151416

References

  • •  DiJoseph et al. 2006. Clin Cancer Res. 12(1):242-9. PMID: 16397048.
  • •  Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma.
  • •  Shen et al. 1988. Int J Cancer. 42(5):792-7. PMID: 3263328.
  • •  Evaluation of four CD22 antibodies as ricin A chain-containing immunotoxins for the in vivo therapy of human B-cell leukemias and lymphomas.
  • •  Bofill et al. 1985. J Immunol. 134(3):1531-8. PMID: 3871452.
  • •  Campana et al. 1985. J Immunol. 134(3):1524-30. PMID: 3918103.
  • •  Human B cell development. II. Subpopulations in the human fetus.
  • •  Human B cell development. I. Phenotypic differences of B lymphocytes in the bone marrow and peripheral lymphoid tissue.